Application of isoorientin in preparation of medicament for resisting respiratory syncytial virus

An anti-respiratory syncytial virus technology, applied in the field of medicine, can solve the problems of non-specific prevention and control measures, high toxicity and side effects, and high cost, and achieve strong anti-respiratory syncytial virus activity, novel mechanism of action, and good application prospects

Active Publication Date: 2010-09-29
GUANGXI WUZHOU PHARMA GRP
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no effective specific prevention and treatment measures for RSV infection. The nucleoside drug ribavirin is the only chemical drug approved by the FDA for the treatment of RSV infection. not ideal
In addition, although RSV antibody drugs (such as RSV monoclonal antibody Synagis) have good curative effect, they have a long use cycle and high cost, and have not been widely used in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of isoorientin in preparation of medicament for resisting respiratory syncytial virus
  • Application of isoorientin in preparation of medicament for resisting respiratory syncytial virus
  • Application of isoorientin in preparation of medicament for resisting respiratory syncytial virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: Anti-respiratory syncytial virus activity of isoorientin in vitro

[0017] (1) Cells, viruses and experimental materials: Respiratory syncytial virus (RSV, Long strain), host cells are laryngeal carcinoma cells (Hep-2 cells); positive control drug is ribavirin (ribavirin); cells grow at a mass percentage concentration 10% fetal bovine serum (FBS) in the MEM medium; the maintenance solution is the MEM medium containing 1% FBS in mass percent concentration.

[0018] (2) Preparation of sample solution: the isoorientin sample (purchased from SIGMA company) and ribavirin sample were made into a solution with a concentration of 40mg / mL with dimethyl sulfoxide (DMSO), and then respectively mixed with maintenance solution. The samples were prepared into 400 μg / mL and 25 μg / mL sample solutions, which were used for cytotoxicity and antiviral activity experiments, respectively.

[0019] (3) measure the cytotoxicity of compound with tetrazolium salt (MTT) colorimetry: ...

Embodiment 2

[0027] Example 2: Determination of in vitro anti-respiratory syncytial virus activity of isoorientin and ribavirin in combination

[0028] (1) Cells, viruses and experimental materials: Respiratory syncytial virus (RSV, Long strain), host cells are laryngeal carcinoma cells (Hep-2 cells); positive control drug is ribavirin (ribavirin); cells grow at a mass percentage concentration 10% fetal calf serum (FBS) MEM medium; the maintenance solution is 1% FBS MEM medium.

[0029] (2) Preparation of sample solution: the isoorientin sample (purchased from SIGMA Company) and ribavirin sample were made into solutions with a concentration of 40mg / mL with dimethyl sulfoxide (DMSO), and the isoorientin samples were respectively mixed with maintenance solution. Orientin and ribavirin were prepared into 5.7 μg / mL and 3.0 μg / mL solutions, and then the two were mixed at a volume ratio of 1:1 to form a sample solution to be tested.

[0030] (3) The cytopathic effect reduction assay was used to...

Embodiment 3

[0033] Example 3: Anti-respiratory syncytial virus activity of isoorientin in vivo

[0034] (1) Animals: Kunming male or female mice (18-22 g).

[0035] (2) Animal experiment: the mouse RSV infection model was used to measure the anti-respiratory syncytial virus (anti-RSV) activity of isoorientin.

[0036] Select 60 BALB / C mice, half male and half female, and randomly divide them into 6 groups, namely high-dose isorientin group (40.0mg / (kg·d)), middle-dose group (20.0mg / (kg·d) )), low dose group (10.0mg / (kg·d)), ribavirin 10mg / (kg·d), virus positive and normal saline negative control group, 10 rats in each group. Intragastric administration, positive and negative control groups intragastric administration of normal saline. Three days later, nasal instillation of RSV suspension (TCID 50 for 10 -6.6 / ml), continue to administer by intragastric administration for 7 days, and observe the survival situation of mice. The mice were sacrificed 40 minutes after the last administra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of isoorientin in preparation of a medicament for resisting respiratory syncytial virus. The medicament for resisting the respiratory syncytial virus contains isoorientin with effective treatment dose and pharmaceutically acceptable carrier. The medicament for resisting the respiratory syncytial virus is prepared into powder, pills, tablets, capsules, oral liquid, aerosol or injection. Aiming at the problem to be emergently solved in the field of treating the current respiratory virus, the invention seeks a new efficient and low-toxicity respiratory virus resistant medicament resource; the isoorientin provided by the invention is a natural monomer compound, and has strong activity for resisting the respiratory syncytial virus and low toxicity on host cells; in addition, in vitro anti-virus experiments show that the isoorientin applied with virazole serving as a clinically common anti-virus medicament has synergistic action. Therefore, the isoorientin has the characteristics of efficient anti-virus activity, low toxicity and novel acting mechanism, and has good application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to the use of isoorientin as a drug for preparing anti-respiratory syncytial virus. Background technique [0002] Isoorientin is a natural source of flavonoid 6-carbon glycosides, which is contained in many medicinal plants. According to the search results of the State Intellectual Property Office, China Journal Network and Scifinder Scholar, there are three public invention patents related to isoorientin: ①A rapid preparation method for several high-purity medicinal substances in Patrinia radiata (Patent No. 200410068016.2 ); ②Cinnabarum chinensis extract and its preparation method, pharmaceutical composition and use (patent number 200710163097.8); ③method for separating and purifying flavonoid glycoside monomers from Mimosa (patent number 200910096967.3). They are respectively the preparation methods for isoorientin to be separated and purified from Patrinia alba, Cap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P31/14A61P11/00
Inventor 李药兰叶文才王英张晓琦范春林
Owner GUANGXI WUZHOU PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap